HekaBio is Biotechnology in Japan that focus on in-vitro diagnostics business. Founded in 2016. They cover business area such as operator, venture, radiation, oncology and fibrotic disease, broad category development expertise, pharma, medical device, in-vitro diagnostic, digital health, cell, gene, therapy, healthcare practitioner, innovation, inflammation, significant therapeutic benefit, healthcare cost saving.
2016
( 10 years old in 2026 )
In-vitro Diagnostics
-
Nihonbashi Muromachi Bldg. 8F
3-3-16 Nihonbashihongokucho
Tokyo, Chuo-ku 103-0021
Japan
Private
operatorventureradiationoncology and fibrotic diseasebroad category development expertisepharmamedical devicein-vitro diagnosticdigital healthcellgenetherapyhealthcare practitionerinnovationinflammationsignificant therapeutic benefithealthcare cost saving
* We use standard office opening hours in near HekaBio's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
HekaBio is Biotechnology business from Japan that founded in 2016 (10 years old in 2026), HekaBio business is focusing on In-vitro Diagnostics.
HekaBio headquarter office and corporate office address is located in Nihonbashi Muromachi Bldg. 8F 3-3-16 Nihonbashihongokucho Tokyo, Chuo-ku 103-0021 Japan.
HekaBio was founded in Japan.
In 2026, HekaBio is currently focus on in-vitro diagnostics sector.
Above is snippet of Google Trends for "in-vitro diagnostics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with HekaBio, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
